Zhe Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhe Yang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Bajin Wei
1 shared publication- Chunyang Xing
Department of Orthopedics, School of Medicine, First Affiliated Hospital of Zhejiang University, Hangzhou, China
1 shared publication - Haiyang Xie
Division of Hepatobiliary and Pancreatic Surgery Department of Surgery The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
1 shared publication - Hengmi Cui
Institute of Epigenetics and Epigenomics, Yangzhou University, Yangzhou, Jiangsu, China
1 shared publication - Junhao Cheng
Software Engineering Institute of Guangzhou,Department of Software Engineering,Guangzhou,China
1 shared publication - Kangjie Chen
School of Cybersecurity, Tianjin University, Tianjin, China
1 shared publication
Latest Publications
- Open Access
- 22 September 2018
- Published by Springer Nature in Biotechnology Letters
- Vol. 40 (11-12) , 1507-1518
Generation of Cas9 transgenic zebrafish and their application in establishing an ERV-deficient animal model
To investigate the effect of endogenous Cas9 on genome editing efficiency in transgenic zebrafish.
- 22 September 2018
- Published by Springer Nature in Biotechnology Letters
- Vol. 40 (11-12) , 1507-1518
Open AccessGeneration of Cas9 transgenic zebrafish and their application in establishing an ERV-deficient animal model
To investigate the effect of endogenous Cas9 on genome editing efficiency in transgenic zebrafish.
- Open Access
- 1 January 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (1) , 94-103
Reversing Effect of Ring Finger Protein 43 Inhibition on Malignant Phenotypes of human Hepatocellular Carcinoma
It has been shown that Ring finger protein 43 (RNF43) is overexpressed in colorectal cancer and mediates cancer cell proliferation; however, its role in hepatocellular carcinoma (HCC) remains unknown. In this study, we found that RNF43 was frequently overexpressed in HCCs, and this overexpression was correlated with positive vascular invasion, poor tumor differentiation, and advanced tumor stage. Functional studies showed that knockdown of RNF43 could induce apoptosis and inhibit proliferation, invasion, colony formation, and xenograft growth of HCCs. Microarray-based gene profiling showed a total of 229 genes differentially expressed after RNF43 knockdown, many of which are involved in oncogenic processes such as cell proliferation, cell adhesion, cell motility, cell death, DNA repair, and so on. These results suggest that RNF43 is involved in tumorigenesis and progression of HCCs and that antagonism of RNF43 may be beneficial for HCC treatment. Mol Cancer Ther; 12(1); 94–103. ©2012 AACR.
- 1 January 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (1) , 94-103
Open AccessReversing Effect of Ring Finger Protein 43 Inhibition on Malignant Phenotypes of human Hepatocellular Carcinoma
It has been shown that Ring finger protein 43 (RNF43) is overexpressed in colorectal cancer and mediates cancer cell proliferation; however, its role in hepatocellular carcinoma (HCC) remains unknown. In this study, we found that RNF43 was frequently overexpressed in HCCs, and this overexpression was correlated with positive vascular invasion, poor tumor differentiation, and advanced tumor stage. Functional studies showed that knockdown of RNF43 could induce apoptosis and inhibit proliferation, invasion, colony formation, and xenograft growth of HCCs. Microarray-based gene profiling showed a total of 229 genes differentially expressed after RNF43 knockdown, many of which are involved in oncogenic processes such as cell proliferation, cell adhesion, cell motility, cell death, DNA repair, and so on. These results suggest that RNF43 is involved in tumorigenesis and progression of HCCs and that antagonism of RNF43 may be beneficial for HCC treatment. Mol Cancer Ther; 12(1); 94–103. ©2012 AACR.